NewAmsterdam Pharma Company N.V. (NAMS) reported Q1 Revenue
Tweet
Share
E-mailGet Alerts NAMS Hot Sheet
Join SI Premium – FREE
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) reported Q1 Revenue for the quarter came in at $3.04 million versus the consensus estimate of $1.18 million.
For earnings history and earnings-related data on NewAmsterdam Pharma Company N.V. (NAMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- Marvell Technology (MRVL) Tops Q2 EPS by 1c, Offers Guidance
- Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
